Article Text

PDF

High-sensitivity troponin assays and the early rule-out of acute myocardial infarction
  1. Anoop S V Shah,
  2. David E Newby,
  3. Nicholas L Mills
  1. BHF/University Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK
  1. Correspondence to Dr Nicholas Mills, BHF/University Centre for Cardiovascular Science, Chancellor's Building, Royal Infirmary, Little France, Edinburgh EH16 4SB, UK; nick.mills{at}ed.ac.uk

Statistics from Altmetric.com

Many patients self-present or are referred by primary care to the emergency department with chest pain because of the potential that they may be suffering an acute myocardial infarction, one of the most common causes of death worldwide.1 Owing to diagnostic uncertainty, the majority of these patients are admitted, and, in some centres, chest pain is responsible for up to 40% of all unplanned hospital admissions.2 The majority of these admissions are unnecessary and place additional burden on healthcare systems that are already struggling to cope with increasing emergency care attendances. Approaches to improve the accurate identification of patients with myocardial infarction would therefore be welcome and a potential major benefit.

Cardiac troponins are regulatory muscle proteins that are released into the circulation after acute myocardial injury. Assays that quantify cardiac isoforms of troponin have greater specificity and sensitivity for the diagnosis of myocardial infarction than traditional cardiac enzymes.3 ,4 Recent advances have led to greatly improved assay sensitivity, permitting quantification of extremely low serum concentrations of troponin with excellent precision. High-sensitivity cardiac troponin assays have limits of detection 10–100-fold lower than contemporary assays and are able to detect troponin in the circulation of the majority of healthy persons.4 These assays have the potential to transform how we assess patients with chest pain in the emergency room.

Myocardial infarction is defined as a rise and/or fall in cardiac troponin with at least one value above the 99th centile upper reference limit in the context of symptoms or clinical evidence of myocardial ischaemia.5 To minimise the potential for misdiagnosis, the National Institute for Health and Clinical Excellence (NICE) guidelines have recommended measuring troponin on admission and 10–12 h after the onset of symptoms to coincide with the peak in circulating troponin concentration.6 These guidelines now need updating to reflect the more widespread use of high-sensitivity troponin assays in the clinic. Indeed the latest guidelines from the Global Task Force recommend that troponin concentrations should be determined on admission and at 3–6 h after admission, irrespective of the timing of onset of symptoms.5 ,7 More sensitive assays permit the detection of smaller amounts of myocardial injury and therefore enable the clinician to make an earlier diagnosis.

Hoeller and colleagues have addressed an important and clinically relevant question.8 Can high-sensitivity troponin assays be used to rule out myocardial infarction with a single measurement of troponin on presentation? This strategy is not endorsed by international guidelines and the answer to the question is unequivocal. Troponin concentrations on presentation were within the normal reference range in up to one-fifth of patients who would subsequently be diagnosed with acute myocardial infarction on repeat sampling. Indeed in patients presenting with symptoms for <3 h, as many as one in two patients with a diagnosis of myocardial infarction had troponin concentrations within the normal reference range on presentation. In these patients, the diagnosis would have been missed if clinicians were to rely on a single measurement of troponin in the emergency department, and the authors conclude that serial sampling is essential for the diagnosis of myocardial infarction.

One of the strengths of the analysis of Hoeller and colleagues is that they evaluate four high-sensitivity assays including two prototype assays that are not yet commercially available. They report differences between assays in the sensitivity of a single admission troponin concentration for a final diagnosis of myocardial infarction determined on serial testing that, if interpreted incorrectly, could infer advantages or disadvantages of one assay over another. Apparent differences in sensitivity between assays are not due to differences in assay precision, but are a consequence of variance in the manufacturers’ recommended 99th centile upper reference limits and the selection of one assay for adjudication of the final diagnosis. The analysis would have been more meaningful if the final diagnosis was adjudicated for each assay in turn or if the upper reference limits, and therefore diagnostic thresholds, were determined for each assay in a single reference population. A recent independent normal reference range study has made a major contribution in this area, reporting upper reference limits that were 3- and 5-fold higher than the manufacturers’ limits for the prototype assays used in the present analysis.9 Hoeller and colleagues also highlight the value of standardisation for cardiac troponin assays. We believe all high-sensitivity cardiac troponin assays should be evaluated in a large independent, multiethnic, age- and sex-varied reference population to determine the normal range as part of the regulatory approval process.

Serial sampling of troponin is important not just to permit the safe rule-out of myocardial infarction, but also to minimise the potential for misdiagnosis in patients with elevated cardiac troponin concentrations. Improvements in assay sensitivity have inevitably reduced specificity for myocardial infarction, as these assays do not define the cause of myocardial injury. Troponin concentrations may be outwith the normal reference range in patients with other acute illnesses and in patients with chronic structural heart diseases, including stable coronary artery disease10 and congestive cardiac failure.11 ,12 It is therefore essential to demonstrate a rise and/or fall in troponin concentration to differentiate acute myocardial infarction from acute or chronic myocardial injury.5 ,7

Innovative algorithms to rule out myocardial infarction in the emergency department based on thrombolysis in myocardial infarction (TIMI) risk score and serial troponin measurement at presentation and 2 h later may permit an additional 40% of patients to be safely discharged.13 Indeed the use of more sensitive assays and earlier detection of myocardial necrosis does improve clinical outcomes.14 The value for the patient, clinician and hospital of a rapid diagnosis is clear, but needs to be offset against the identification of increasing numbers of patients with elevated troponin concentrations due to non-acute coronary syndrome pathologies.15 Hoeller and colleagues’ use of the manufacturers’ recommended upper reference limits, as low as 9 ng/L for two prototype cardiac troponin I assays, highlights the potential for harm. For every patient with an admission troponin concentration >9 ng/L correctly diagnosed with myocardial infarction, another patient who did not have acute myocardial infarction was identified. As such, the positive predictive value of an elevated admission troponin concentration was as low as 45% even in a well-selected population of patients with symptoms suggestive of myocardial infarction. When these assays are used more widely in the emergency department, the use of inappropriate diagnostic thresholds that have not been independently validated have the potential to result in widespread misdiagnosis, unnecessary hospitalisation and investigation, with a detrimental effect on clinical outcomes that may undermine the benefits of an earlier diagnosis of myocardial infarction.

The work of Hoeller and colleagues is important and highlights the need for assay standardisation, robust independent assessment of the normal reference range using an appropriate reference population, and the need for careful evaluation of the impact of high-sensitivity cardiac troponin assays on clinical care.

References

View Abstract

Footnotes

  • Contributors All authors contributed to writing the manuscript.

  • Funding British Heart Foundation Intermediate Fellowship (FS/10/024/28266), Clinical Research Fellowship (SS/CH/09/002 and British Heart Foundation Chair (CH/09/002)).

  • Competing interests NLM has received honoraria for Abbott Diagnostics and acted as a consultant for Beckman-Coultar and Abbott Diagnostics.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Acute coronary syndromes
    Rebeca Hoeller María Rubini Giménez Tobias Reichlin Raphael Twerenbold Christa Zellweger Berit Moehring Karin Wildi Michael Freese Claudia Stelzig Beate Hartmann Melanie Stoll Tamina Mosimann Miriam Reiter Philip Haaf Mira Mueller Bernadette Meller Thomas Hochgruber Cathrin Balmelli Seoung Mann Sou Karsten Murray Heike Freidank Stephan Steuer Jan Minners Stefan Osswald Christian Mueller